UniQure’s AMT-130 Gene Therapy for Huntington’s Disease

UniQure stock doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease ...
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...
Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
The U.S. FDA has greenlit the first steps of Uniqure NV’s accelerated approval pathway for gene therapy AMT-130 to treat Huntington’s disease. The agency said data from the ongoing phase I/II studies ...
Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
The Wicked Witch of the West and I have something in common: We both use our fatal flaws to our advantage—for her, her green ...
Tapering. Spaghetti plots show that CSF NFL (right) rises more quickly in people with ADAD mutations (red) than in noncarriers (gray) and that this accelerates as disease progresses. In plasma (left), ...
Madison Elsaadi, an analyst from B.Riley Financial, reiterated the Buy rating on Wave Life Sciences (WVE – Research Report). The associated ...